INS and prostate carcinoma: Lower risks of breast (n = 15; RR = 0.90; 95% CI = 0.82–0.98; Table 2) and prostate cancers (n = 7; RR = 0.74; 95% CI = 0.56–0.98; Table 5) were found among insulin users compared with nonusers.